Newron Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to sarizotan for the treatment of Rett syndrome.

Sarizotan is a 5HT1A agonist and D2 agonist/antagonist. During preclinical testing, sarizotan has shown a 70–85% reduction in apneas and hyperventilation episodes with both acute and chronic dosing.

RELATED: Neurologic Disorders Resource Center

Newron also recently announced that the FDA had accepted for filing the New Drug Application (NDA) for Xadago (safinamide) as add-on therapy in both early and mid-to-late stage Parkinson’s disease (PD) patients who are inadequately managed on their current treatment.

For more information visit Newron.com.